Fig. 2

The value of tumor mutation burden and alteration of bases according to histological subtypes. The TMB value of group A was significantly higher than that of group B. Alterations in KRAS, tumor suppressor protein p53 (TP53), and cyclic adenosine monophosphate response element binding protein binding protein (CREBBP) were recognized in eight, six, and five cases, respectively. Other bases with alterations listed included one case each

Other abbreviations

MCI, mucinous carcinoma with infiltrative invasion. MCE, mucinous carcinoma with expansile invasion. MBT, mucinous borderline tumor; FIGO, International Federation of Obstetrics and Gynecology; TMB, tumor mutation burden; Mut, mutations; Mb, megabase; TP53, tumor suppressor protein p53; CDKN2A, cyclin-dependent kinase inhibitor 2 A; BRAF, v-raf murine sarcoma viral oncogene homolog B1; MTOR, Mammalian target of rapamycin; PIK3CA, phosphatidylinositol-4,5-bisphosphate 3kinase catalytic subunit alpha; ARID1A, the AT-rich interactive domain 1 A; CDK12, Cyclin-dependent kinase 12; CREBBP, cyclic adenosine monophosphate response element binding protein binding protein; NOTCH, Neurogenic locus notch homolog protein; TSC2, Tuberous Sclerosis Complex 2; FANCA, Fanconi anaemia, complementation group A; ATR, Ataxia-Telangiectasia-mutated- and Rad3-related; PTEN, phosphatase and tensin homolog; GNAS, Galpha encoding guanine nucleotide binding protein, alpha-stimulating; FGFR2, Fibroblast growth factor receptor 2; STK11, Serine/threonine kinase 11